Parkinson's Disease G2019S LRRK2 Genetic Testing Program
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Increase awareness of the G2019S LRRK2 mutation in Parkinson's and no cost genetic testing program.
Condition or disease
Genetic: G2019S LRRK2
This program is intended to increase awareness of genetic Parkinson's, in particular the G2019S LRRK2 mutation, and provide no cost genetic testing to determine if they carry the G2019S LRRK2 mutation.
Identify Parkinson's patients with the G2019S mutation in their LRRK2 gene [ Time Frame: 2 years ]
To identify Parkinson's patients with the G2019S mutation in their LRRK2 gene through whole exome sequencing in order to support the development of an oral precision medicine.
Secondary Outcome Measures :
Understand the proportion of Parkinson's patients who have a G2019S LRRK2 mutation [ Time Frame: 2 years ]
To obtain information about the proportion of Parkinson's patients who have a G2019S LRRK2 mutation.
Increase awareness of the importance of genetic testing in Parkinson's disease [ Time Frame: 2 years ]
To increase healthcare provider and patient awareness of the importance of genetic testing in Parkinson's disease in order to be aware of potential eligibility for clinical studies of genetic targeted medicines.
Increase interest of healthcare providers and patients participation in clinical trials [ Time Frame: 2 years ]
To engage healthcare providers and patients' interest in participation in upcoming clinical studies.
Biospecimen Retention: Samples With DNA
Data generation using next-generation sequencing (NGS) of human exons
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
A clinical diagnosis of Parkinson's disease
Participants include those with a clinical diagnosis of Parkinson's, in particular those who have a first- or second-degree relative with Parkinson's, or who have young onset Parkinson's (age less than 50 at diagnosis) or are of Ashkenazi Jewish or North African Berber descent, or have a relative with a known genetic mutation in the LRRK2 gene, or who have a genetic mutation in the LRRK2 gene.
Participant eligible for enrollment in the program must meet all of the following criteria:
Participant must be a person diagnosed with Parkinson's disease who is 18 years or older.
Participant is under the care of a physician for their Parkinson's disease.
Participant is able to read, write and understand English, and reside in a country where the shipment of biological samples is allowed.
Participant is able to grant informed consent.
In the case of participants, willing to participate in a free genetic testing program to determine if they carry the G2019S LRRK2 mutation.
Willing to be notified of eligibility for clinical studies (if appropriate).
Particpants who already believe they have tested positive for the mutation will be allowed to be retested through this program and be notified of potential eligibility for studies.
Inability to meet any of the inclusion criteria.
Participant has received on of the following advanced treatments to manage their Parkinson's: gene therapy, deep brain stimulation (DBS), injections into the brain, continuous infusion of medication into their stomach/intestines with a pump.